Restoration of endometrial receptivity and reproductive function in infertile women with excess body weightand complex non-atypical endometrial hyperplasia
DOI:
https://doi.org/10.12775/JEHS.2022.12.01.044Keywords
infertility, complex non-atypical endometrial hyperplasia, excess body weight, body mass index, endometrium, implantation window, endometrial receptivity, pinopodia, implantation molecules, hormones, steroid hormone receptors, lipokines, insulin resistance, hysteroscopy, gonadotropin-releasing hormone agonists, metformin, fenofibrate, indole-3-carbinol, myo-inositol, corosolic acid, pregnancyAbstract
To date, there are several approaches to the treatment of endometrial hyperplasia, but it is quite unclear which approach provides a higher clinical response with a lower recurrence rate, in addition to preservation and restoration of fertility in infertile women with complex non-atypical endometrial hyperplasia (NEH) and excess body weight. The purpose of the study was to evaluate the effectiveness of the restoration of reproductive function in patients with infertility, complex NEH and with excess body weight according to the proposed method. Material and methods. 74 women of reproductive age with complex NEH, infertility and excess body weight were under observation, of which 34 patients of the main group after hysteroscopic resection of the lesion at the first stage of treatment, at the second stage of treatment received gonadotropin-releasing hormone agonists (aGnRH) and adjuvant therapy with drugs indole-3-carbinol, metformin, fenofibrate for three months, and then at the third stage of treatment dydrogesterone, metformin, a vitamin-mineral complex that included myo-inositol, banaba leaves, extract of 1% corosolic acid, vitamin D3, methylfolate-quatrafolic, chromium for 6 months. 40 patients of the control group after hysteroscopic resection of the lesion at the first stage of treatment were prescribed aGnRH for 3 months in the second stage of treatment, then methylfolate-mvatrafolic for 6 months. Anthropometric data, echometric and morphofunctional characteristics of the endometrium during the expected window of implantation, hormonal profile and levels of peripheral blood lipokines in the dynamics of treatment were studied. Reproductive results were evaluated within a year after the end of treatment. The results. Treatment of complex NEH in the main group led, compared to the control group, to a decrease in body mass index, improvement in echometric and morphofunctional characteristics of the endometrium, its receptivity during the expected window of implantation, hormonal profile and lipokines level in peripheral blood, a decrease in insulin resistance, and an increase in the frequency of pregnancy. Conclusion. The proposed scheme for the treatment of complex NEH in infertile women with excess body weight allowed to improve their reproductive results, is effective and can be recommended for implementation in wide clinical practice.
References
Ahern T, Doherty K, Kapeluto D, Davis M, Mulholland U, Rossiter E, et al. Body mass index estimation and measurement by healthcare professionals. Open Journal of Preventive Medicine. 2012;2:265–271. doi: 10.4236/ojpm.2012.23038.
Armstrong AJ, Hurd WW, Elguero S, Barker NM, Zanotti KM. Diagnosis and management of endometrial hyperplasia. J Minim Invasive Gynecol. 2012 Sep-Oct;19(5):562-71. doi: 10.1016/j.jmig.2012.05.009.
Cholakian D, Hacker K, Fader AN, Gehrig PA, Tanner EJ 3rd. Effect of oral versus intrauterine progestins on weight in women undergoing fertility preserving therapy for complex atypical hyperplasia or endometrial cancer. Gynecol Oncol. 2016 Feb;140(2):234-8. doi: 10.1016/j.ygyno.2015.12.010.
Falcone F, Laurelli G, Losito S, Di Napoli M, Granata V, Greggi S. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J Gynecol Oncol. 2017 Jan;28(1):e2. doi: 10.3802/jgo.2017.28.e2.
Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989 Jan;160(1):126-31. doi: 10.1016/0002-9378(89)90103-8.
Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012 May;125(2):477-82. doi: 10.1016/j.ygyno.2012.01.003.
Koskas M, Yazbeck C, Walker F, Delorme P, Azria E, Luton D, et al. Traitementconservateur du cancer et des hyperplasiesatypiques de l'endomètreenvue de préserver la fertilité : revue de la littérature [Fertility sparing management of endometrial adenocarcinoma and atypical hyperplasia: a literature review]. Bull Cancer. 2012 Jan;99(1):51-60. French. doi: 10.1684/bdc.2011.1516.
Vitale SG, Riemma G, Carugno J, Chiofalo B, Vilos GA, Cianci S, et al. Hysteroscopy in the management of endometrial hyperplasia and cancer in reproductive aged women: new developments and current perspectives. Transl Cancer Res. 2020 Dec;9(12):7767-7777. doi: 10.21037/tcr-20-2092.
Yasin HK, Taylor AH, Ayakannu T. A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer. Cancers (Basel). 2021 Apr 29;13(9):2149. doi: 10.3390/cancers13092149.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 O. Nosenko, S. Yurchenko
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 250
Number of citations: 0